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Background
The Wilms tumour antigen 1 (WT1) is a self-antigen
expressed at high levels in leukaemic cells, but not in
healthy tissue. WT1, therefore, is a favourable target
antigen for allogeneic T cell therapy to prevent leukae-
mic relapse after stem cell transplantation. However, a
comprehensive characterisation of CD4+ and CD8+
WT1-specific T cells is missing and the efficient expan-
sion of a polyclonal WT1-reactive T cell population for
clinical use has remained a major challenge.
In this study we aim to directly ex vivo characterize
WT1-specific T cells present in the blood of healthy
donors at high-resolution and to develop a method for the
rapid generation of functionally potent, polyclonal CD4+
and CD8+ WT1-specific T cells for clinical use.
Methods
We utilise the magnetic enrichment of activation marker
expressing cells after antigen-specific stimulation, as low
frequencies of WT1-specific T cells in healthy donors
do not allow direct detection.
Results
Ex vivo frequencies of WT1-specific T cells range between
10-6 and 10-5 WT1-specific T cells within CD4+ T cells. In
about 80% of healthy donors (n=15) a CD4+ memory
response, accompanied by production of effector cytokines
like IFN-g and TNF-a against WT1 peptides is present. In
contrast, detected CD137+CD8+ WT1-reactive T cells
exhibit a naïve phenotype (CD45RA+CCR7+) in all tested
donors (n=5).
An improved short-term expansion protocol to gener-
ate potent WT1-specific T cell cultures for clinical use
was established utilising a CD137+ cell enrichment step.
Notably, a high frequency of expanded CD4+ and CD8+
T cells show specific reactivity against WT1-presenting
autologous cells as detected by production of effector
cytokines after antigen-specific restimulation. Cytotoxic
activity against antigen-loaded target cells could be
shown by direct flow-cytometry-based cytotoxicity
assays and antigen-specific upregulation of the degranu-
lation marker CD107a. WT1-MHCI-Tetramerstainings
furthermore confirmed antigen-specificity and suggested
polyclonality within the CD8+ T cell population. In con-
trast to previous expansion protocols our polyclonally
expanded T cells exhibit a favourable, unexhausted
memory phenotype, express co-stimulatory markers
CD27 and CD28 and the IL7R-a chain (CD127).
Conclusions
Functional, polyclonal CD4+ and CD8+ WT1- reactive
T cells can be efficiently enriched directly ex vivo from the
natural repertoire by magnetic separation of T cells after
antigen-specific stimulation. Thus, our approach holds
great potential for the GMP-compliant generation of
WT1-specific T cells for future clinical use.
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